NRAS and melanoma: In vitro and in vivo studies revealed that SR4 and niclosamide, two small molecules mitochondria uncouplers, can be used successfully in the treatment of naïve wild type, BRAFV600E and NRAS mutants, vemurafenib-resistant melanomas and melanomas with greater OXPHOS phenotype (Table 1).